Neurostimulation to Register Fastest CAGR in Overactive Bladder Treatment Market During 2022-2028

According to our latest study on "Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Pharmacotherapy and Disease Type," the market is projected to reach US$ 5,333.92 million by 2028 from US$ 4,295.93 million in 2021; it is expected to grow at a CAGR of 3.1% from 2022 to 2028. The report highlights the key factors driving the market and prominent players with their developments in the market.

The overactive bladder treatment market witnessed growth due to increased overactive bladder symptoms observed in COVID-19-recovered patients. COVID-19 virus not only affected the respiratory tract of the body, but it also affected the bladder of the patient. Further, COVID-19 infection resulted in urine cytokine elevation that increased urination frequency, leading to overactive bladder disorder among COVID-19 patients. According to a study by American Urological Association, patients with COVID-19 infections were at an increased risk for developing new or worsening overactive bladder symptoms. Moreover, approximately one-third of patients with COVID-19 reported a significant increase in clinical symptoms during the International Consultation on Incontinence Questionnaire Overactive Bladder Module (ICIQ-OAB) conducted two months after infection.

Based on pharmacotherapy, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, intravesical instillation, and neurostimulation. The neurostimulation segment is further segmented into transcutaneous sacral nerve stimulation, transcutaneous tibial nerve stimulation, percutaneous posterior tibial nerve stimulation, and others. The anticholinergics segment is further segmented into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and other anticholinergics. The mirabegron segment held the largest share of the market in 2021, and the neurostimulation segment is anticipated to register the highest CAGR in the market during the forecast period. Based on disease type, the overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic overactive bladder. The idiopathic overactive bladder segment held a larger market share in 2021, and it is also anticipated to register a higher CAGR in the market during the forecast period.

Urinary incontinence is the loss of bladder control caused due to the improper functioning of the muscles and nerves that control the passage of urine through the bladder. According to the National Association for Incontinence data, in 2018, ~200 million people worldwide were affected by urinary incontinence. Stress incontinence and urge incontinence are the two common types of urinary incontinence affecting women, wherein the latter is also known as overactive bladder. As per the data provided by Office on Women's Health a division of the US Department of Health and Human Services, the prevalence of incontinence in women is twice as in men, and aging, pregnancy, childbirth, and menopause can be the key factors leading to this condition in women. Other factors affecting the function of muscles and nerves include being overweight, constipation, or pelvic surgeries. As stated by the North American Menopause Society (NAMS), in the US, the prevalence of urinary incontinence was 17.1% among women aged 20 years or more and 38% in women aged 60 years and older in 2021. Although urinary incontinence may affect women at any age, it is more common in older women, mainly due to hormonal changes during menopause. According to the National Health Service (NHS), ~4 in every ten women aged 65 and older have urinary incontinence. As per the HCA UK (a healthcare provider), ~3 million people in the UK are affected by urinary incontinence, of which 15% of women and ~5% of men are in their mid-40s. Thus, the growing prevalence of urinary incontinence favors the growth of the overactive bladder treatment market.

Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Pfizer Inc.; AbbVie Inc; Teva Pharmaceutical Industries Ltd; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co.Inc; Medtronic Plc; Allergan; and Colorado Urology Associates, PLLC are among the leading companies operating in the overactive bladder treatment market.

In terms of geography, the overactive bladder treatment market has been segmented as follows:

Based on geography, the overactive bladder treatment market is primarily segmented into North America, Europe, Asia Pacific, the Middle East & Africa (MEA), and South & Central America. The market in North America is further segmented into the US, Canada, and Mexico. The European market is subsegmented into France, Germany, the UK, Spain, Italy, and the Rest of Europe. The overactive bladder treatment market in APAC is segmented into Japan, China, India, Australia, South Korea, and the Rest of Asia Pacific. The overactive bladder treatment market in the MEA is further segmented into Saudi Arabia, the UAE, South Africa, and the Rest of the Middle East& AFrica. The market in South & Central America is further segmented into Brazil, Argentina, and the Rest of South & Central America.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com